Connect with us

Technology

ImpediMed Secures $15m Growth Capital Funding

Published

on

New round will help fuel commercialization efforts in support of ImpediMed’s platform technology for the detection and monitoring of lymphedema.

CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ — ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.

With this new funding in place, ImpediMed’s capital base is well equipped to support the continued execution of its commercial strategy. As a result, the company is better positioned than ever to achieve its long-term goals and create significant value for its shareholders.

As a pioneer in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL) –– the SOZO® Digital Health Platform. ImpediMed’s platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health payors now providing coverage for over 258 million covered lives.

Lymphedema, a common consequence of cancer treatment, is challenging to detect before symptoms appear. ImpediMed’s SOZO® Digital Health Platform uses BIS to identify fluid changes early, enabling intervention before lymphedema becomes a chronic condition. With growing adoption in clinical practice and increasing payor coverage, ImpediMed’s innovative approach is transforming lymphedema management.

In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its accreditation standards to include lymphedema prevention programs utilizing BIS as an evidence-based guideline for managing lymphedema. The NAPBC is a quality program of the American College of Surgeons, and accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care. This recognition further validates BIS as a critical tool in lymphedema management and presents a significant opportunity for ImpediMed to expand its reach, driving broader adoption of the SOZO Digital Health Platform across breast cancer centers nationwide.1

“We are pleased with our agreement with SWK Holdings and the confidence they have shown in ImpediMed, as well as in the future of our SOZO Digital Health Platform,” said Dr. Parmjot Bains, MD, CEO & Managing Director of ImpediMed. “SWK’s proven approach of supporting innovative healthcare companies makes them an ideal partner for us as we pursue our commercial growth strategy over the next five years. We are confident with the business’ direction, and this was reinforced throughout our due diligence process. In conjunction with our existing cash reserves, this facility gives us the time and funding flexibility required to execute on our business plan and fully capitalize on the BCRL opportunity.”

“We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes,” said JD Tamas, Director of Underwriting at SWK Holdings. “We are excited to provide this capital to support ImpediMed’s continued mission to improve the lives of patients by pushing the boundaries of what’s possible in fluid and tissue analysis.”

About SOZO Digital Health Platform

SOZO, the world’s most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

About SWK Holdings

SWK Holdings is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK’s unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK’s solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million

About Armentum Partners

Armentum Partners is an investment bank dedicated to assisting healthcare and technology companies access non-dilutive capital.   Since the beginning of 2023, Armentum has raised over $3.5 billion for its clients.

About ImpediMed

Founded in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.

For more information, visit www.impedimed.com.

1 Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American College of Surgeons. Content does not reflect the views or interpretations of the American College of Surgeons.

Media Contact:
Jodi Perkins
Amendola Communications, on behalf of ImpediMed
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/impedimed-secures-15m-growth-capital-funding-302371333.html

SOURCE ImpediMed

Continue Reading

Technology

Visier Debuts Talent Agents, Closing the Gap Between HR Programs and Business Impact

Published

on

By

New AI agents turn Visier insights and plans into guided action for every manager, fixing the #1 reason HR programs fail: manager follow-through

VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ — Visier today announced Talent Agents at HR Tech 2026. Built on the Visier Workforce Intelligence Platform, these new AI agents guides every manager to the next right action in their organization’s HR programs in real time, and give talent leaders evidence of what each program actually changed for the business.

Talent management devotes a great deal of money and effort into HR programs every year, and many still can’t show the ROI or outcomes. New Visier research* found:

62% of HR leaders name manager follow-through as the single biggest reason programs fail77% of enterprises run HR programs on spreadsheets or a patchwork of tools, and are three times less likely to measure results while a program is underway.

Visier Talent Agents are built to close these gaps, helping talent management tackle its most critical challenges as organizations plan, grow and retain their talent. They leverage the latest in AI developments to pair best-in-class program frameworks with personalized, in-workflow guidance delivered to whoever needs to act next, and a closed-loop system for continuous learning and improvement based on every program’s goals.

“Good program design has never been enough. What HR has lacked is a GPS for every manager, so the moment someone drifts off track, they’re guided back before the program goes sideways,” said Dave Weisbeck, Chief Strategy Officer at Visier. “That’s what Talent Agents deliver, along with proof of what the program actually changed for the business.” 

“The space between HR program design and the actual business result is exactly where most HR investment gets lost,” said Madeline Laurano, founder of Aptitude Research. “Guidance that activates the manager at the moment they need to act, with proof of what changed afterward, is the piece of talent management that’s been missing and what Visier is solving for.”

Unlike HCM suites that teams would spend a year customizing, or point solutions that only see one piece of the picture, or even an internal-built tool that puts employee data at risk, Visier’s Talent Agents are built to run programs end-to-end and prove impact, not just track activity.

The agents reach every stakeholder in a program at the moment they need to act, not just when someone remembers to ask. They’re built to match how an organization actually operates, and the outcome of every action it recommends feeds back into the AI learning engine, so guidance gets sharper with each cycle. Because guidance runs on Visier’s proprietary Workforce AI rather than routing every follow-up through a person, organizations can scale their programs without being constrained by HRBP headcount.

The agents are built on Visier’s Workforce Intelligence Platform, so every program comes with the context, governance, and security an enterprise expects, backed by over 16 years of experience solving HR’s toughest problems.

Talent Agents are Visier’s answer to what the company calls the “activate” layer of Workforce AI, building on the platform’s existing strength in helping organizations understand their workforce data and plan around it. The offering pairs Visier’s technology with a dedicated implementation team that customizes each program to a customer’s specific processes and goals.

Attending HRTech 2026 in Las Vegas this week? Head over to Visier Booth #5209 to explore Talent Agents, or visit visier.com to learn more. The Visier team will also be at UNLEASH World in Paris (booth #106) and Total Talent Asia (booth #3).

About Visier
Visier Workforce AI is the context foundation for talent management. The Visier Workforce Intelligence Platform turns scattered, sensitive people data into one governed understanding of the entire workforce, so organizations can understand, plan, and activate all of their talent priorities in one place. More than 85,000 of the world’s most complex organizations, including Ford Motor Company, eBay, Experian, and Domino’s Pizza, rely on Visier’s over 16 years of workforce domain expertise, ranked #1 in vendor satisfaction and user experience for three consecutive years by the Sapient Insights HR Systems Survey. Learn more at Visier.com.

*Research from fall 2026, conducted by the Visier, Inc. Research Team surveyed verified senior HR and Talent leaders from 80 organizations with more than 10,000 employees across North America.  

visierpr@walkersands.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/visier-debuts-talent-agents-closing-the-gap-between-hr-programs-and-business-impact-302915328.html

SOURCE Visier

Continue Reading

Technology

HSG Laser Unveils New Flagship Machine at EuroBLECH 2026, Powering Productivity for European Manufacturers

Published

on

By

HANNOVER, Germany, Oct. 21, 2026 /PRNewswire/ — HSG Laser is showcasing its latest laser cutting and intelligent manufacturing solutions at EuroBLECH 2026, held from October 20–23 at the Hannover Exhibition Centre. Under the theme “Powering Productivity with HSG,” HSG is presenting its latest innovations at Booth 15-F42, including the European debut of its new flagship GV, alongside the launch of GFA PRO and AI CutPilot, as well as the European debut of its high-speed laser solutions G3015T and R2 PRO.

Expanding High-Performance Laser Solutions

The new GFA PRO is engineered for large-format metal processing, addressing challenges such as large footprints, low speed, unstable thick-plate performance, and high operating costs. Making their European debut, the G3015T and R2 PRO expand HSG’s high-speed laser lineup for sheet and tube processing, helping manufacturers improve throughput, flexibility, and production efficiency.

“HSG Laser’s European footprint has grown steadily, with more than 2,000 units delivered and a new showroom opening soon this year,” said Shawn Wang, Vice President of HSG Laser. “Our latest launches at EuroBLECH mark another step forward, combining high-performance equipment with intelligent technologies and localized support to deliver greater productivity for European customers.”

Recognized by MM MaschinenMarkt Germany

Built for the European market, HSG Laser earned the “International Spotlight” award from MM MaschinenMarkt Germany’s Chief Editor for its GV and AI CutPilot. The GV combines cutting, beveling, countersinking, and chamfering in one machine to streamline pre-welding workflows and boost efficiency. AI CutPilot is HSG’s industry-first, self-developed AI system that turns laser-cutting expertise into a reusable, scalable machine capability, helping reduce trial work and improve first-pass yield. The award further highlights HSG Laser’s technological strength and growing presence in the European market.

Strengthening Local Operations in Europe

As part of its continued commitment to supporting manufacturers worldwide, HSG Laser is further strengthening its localized operations in Europe. On 10th November, HSG will open its new showroom in Düsseldorf, Germany under the theme “Go Global, Link Local.” The new showroom will bring HSG’s latest machines, technologies, and expertise closer to European customers, creating more opportunities for direct engagement and local support. This expansion further strengthens HSG’s presence in Europe and its ability to provide responsive, customer-focused solutions tailored to local manufacturing needs.

About HSG Laser

Founded in 2006, HSG Laser is a leading global manufacturer of intelligent metal processing equipment, specializing in laser cutting, tube processing, bending, and welding automation systems. With a presence in over 100 countries and regional centers across Europe, North America, Japan, India, and Asia-Pacific, HSG Laser is committed to driving the transformation of manufacturing through innovation, reliability, and artificial intelligence.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hsg-laser-unveils-new-flagship-machine-at-euroblech-2026-powering-productivity-for-european-manufacturers-302915275.html

Continue Reading

Technology

Mérieux NutriSciences Completes Acquisition of Certified Group, Becoming North America’s Leading Food Testing Provider

Published

on

By

CHICAGO, Oct. 21, 2026 /PRNewswire/ — Mérieux NutriSciences, a global leader in food safety, quality, and sustainability, today announced the successful completion of its acquisition of Certified Group.

First announced in August 2026, this strategic transaction unites two complementary leaders in the Testing, Inspection, and Certification (TIC) sector. With approximately $300 million in revenue, Certified Group brings 31 laboratories and over 1,600 talented employees into Mérieux NutriSciences’ global network. The integration also adds a robust roster of more than 170 independent regulatory consultants across the United States and Canada.

With this expanded coast-to-coast footprint, Mérieux NutriSciences is positioned to provide customers with broader service offerings and enhanced regulatory support. The integration deepens the company’s capabilities in key Food & Beverage segments, most notably in animal protein through its Food Safety Net Services (FSNS) network, where Certified Group has built a strong reputation as a bellwether for safety and quality, alongside leading positions in dairy, packaged foods, nuts, and spices.

Customers will also benefit from high-value expertise in cosmetics, OTC products, and dietary supplements through the Certified Laboratories vertical, and reduced-harm nicotine product testing via Labstat International. These core verticals are further bolstered by specialized expert services, including contract research (Lab Plus), regulatory consulting (EAS Consulting Group), and comprehensive certification and audit programs (FSNS Certification and Audit).

“We are thrilled to officially welcome the talented teams from Certified Group to the Mérieux NutriSciences global network,” said Nicolas Cartier, CEO of Mérieux NutriSciences. “By combining our respective strengths, we are vastly expanding the depth and breadth of our capabilities. This milestone allows us to be closer to our customers, meeting their localized, time-sensitive needs with unmatched speed and reliability, while furthering our shared purpose: Better Food. Better Health. Better World.”

“Our priority is to ensure a seamless transition for all customers while delivering immediate, enhanced value,” added Sébastien Moulard, President North America at Mérieux NutriSciences. “Through this nationwide analytical network, customers now have access to a truly comprehensive portfolio of routine testing, specialized analysis, expert regulatory support, and more. We are excited to leverage the best of both worlds to drive innovation and provide practical solutions right where production happens.”

“Certified Group has built a differentiated platform with a strong reputation for quality, scientific excellence and exceptional customer service,” said Deborah Kerr, Managing Director, Warburg Pincus & Executive Chair, Certified Group. “We are proud to have supported Certified Group’s evolution and look forward to seeing the company continue to thrive as part of Mérieux NutriSciences.”

The financing of the acquisition brings new minority shareholders Peugeot Invest and Continental Grain Company (Conti) alongside Mérieux NutriSciences’ long standing shareholders: Institut Mérieux, Sofina, and Dassault Group. This collective support underscores strong market confidence in the company’s strategic vision. Ultimately, the successful integration of Certified Group solidifies Mérieux NutriSciences as the leading provider in North America and a top player in the global food TIC market, further cementing its role as the trusted partner for customers navigating a rapidly evolving landscape.

About Mérieux NutriSciences:

At Mérieux NutriSciences, we leverage 60 years of scientific and entrepreneurial expertise to answer food industry needs. Today’s global challenges transform the way food is produced, marketed and consumed, which is why we know our clients need more than reliable analytical results; they need practical and innovative solutions that will contribute to make food systems safer, healthier and more sustainable. Present worldwide, we are more than 160 accredited laboratories and a team of over 11,600 committed employees. We strongly believe that together, we can create solutions to offer our planet: BETTER FOOD. BETTER HEALTH. BETTER WORLD. na.mxns.com

MERIEUX NUTRISCIENCES
Stephen Nichols (North America)
stephen.nichols@mxns.com 

Marion Bertrand (Global)
media@mxns.com 

Ashton van den Bergh (Global)
media@mxns.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/merieux-nutrisciences-completes-acquisition-of-certified-group-becoming-north-americas-leading-food-testing-provider-302915607.html

SOURCE Mérieux NutriSciences

Continue Reading

Trending